Evidence-Based Expert Consensus Regarding Long-Acting Injectable Antipsychotics for Schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN)-Reference-Cited by-同舟云学术

Evidence-Based Expert Consensus Regarding Long-Acting Injectable Antipsychotics for Schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN)

Published:2021-07-27 Issue:8 Volume:35 Page:893-905
ISSN:1172-7047
Container-title:CNS Drugs
language:en
Short-container-title:CNS Drugs

Author:

Yang Kai-Chun,Liao Yin-To,Yang Yen-Kuang,Lin Shih-Ku,Liang Chih-Sung,Bai Ya-Mei

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical)

Link

https://link.springer.com/content/pdf/10.1007/s40263-021-00838-5.pdf

Reference76 articles.

1. Saito Y, Sakurai H, Kane JM, Schooler NR, Suzuki T, Mimura M, et al. Predicting relapse with residual symptoms in schizophrenia: a secondary analysis of the PROACTIVE trial. Schizophr Res. 2020;215:173–80.

2. Krogmann A, Peters L, von Hardenberg L, Bödeker K, Nöhles VB, Correll CU. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectr. 2019;24(S1):38–69.

3. Kane JM, Agid O, Baldwin ML, Howes O, Lindenmayer J-P, Marder S, et al. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry. 2019;80(2). https://doi.org/10.4088/JCP.18com12123.

4. Kane JM, Correll CU. Optimizing treatment choices to improve adherence and outcomes in schizophrenia. J Clin Psychiatry. 2019;80(5). https://doi.org/10.4088/JCP.IN18031AH1C.

5. Tohen M, Goldberg JF, Hassoun Y, Sureddi S. Identifying profiles of patients with bipolar I disorder who would benefit from maintenance therapy with a long-acting injectable antipsychotic. J Clin Psychiatry. 2020;81(4). https://doi.org/10.4088/JCP.OT19046AH1.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the impact of long‐acting injectable compared to oral antipsychotic medications on readmission to a state psychiatric hospital;Journal of Psychiatric and Mental Health Nursing;2024-06-22

2. In-Hospital Use of Long-Acting Injectable Antipsychotics and Readmission Risk in Patients With First-Admission Schizophrenia in Taiwan;JAMA Network Open;2024-06-17

3. Risk of Cardiovascular Events in Schizophrenic Patients Treated with Paliperidone Palmitate Once-Monthly Injection (PP1M): A Population-Based Retrospective Cohort Study in Taiwan;Clinical Drug Investigation;2024-04-15

4. Discovery of potential TAAR1 agonist targeting neurological and psychiatric disorders: An in silico approach;International Journal of Biological Macromolecules;2024-04

5. Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia;CNS Drugs;2024-01